Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 22:12:879089.
doi: 10.3389/fonc.2022.879089. eCollection 2022.

Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients

Sebastian Zschaeck  1   2 , Stephanie Bela Andela  1 , Holger Amthauer  3 , Christian Furth  3 , Julian M Rogasch  2   3 , Marcus Beck  1 , Frank Hofheinz  4 , Kai Huang  3
Affiliations

Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients

Sebastian Zschaeck et al. Front Oncol. .

Abstract

Background: PSMA PET is frequently used for staging of prostate cancer patients. Furthermore, there is increasing interest to use PET information for personalized local treatment approaches in surgery and radiotherapy, especially for focal treatment strategies. However, it is not well established which quantitative imaging parameters show highest correlation with clinical and histological tumor aggressiveness.

Methods: This is a retrospective analysis of 135 consecutive patients with non-metastatic prostate cancer and PSMA PET before any treatment. Clinical risk parameters (PSA values, Gleason score and D'Amico risk group) were correlated with quantitative PET parameters maximum standardized uptake value (SUVmax), mean SUV (SUVmean), tumor asphericity (ASP) and PSMA tumor volume (PSMA-TV).

Results: Most of the investigated imaging parameters were highly correlated with each other (correlation coefficients between 0.20 and 0.95). A low to moderate, however significant, correlation of imaging parameters with PSA values (0.19 to 0.45) and with Gleason scores (0.17 to 0.31) was observed for all parameters except ASP which did not show a significant correlation with Gleason score. Receiver operating characteristics for the detection of D'Amico high-risk patients showed poor to fair sensitivity and specificity for all investigated quantitative PSMA PET parameters (Areas under the curve (AUC) between 0.63 and 0.73). Comparison of AUC between quantitative PET parameters by DeLong test showed significant superiority of SUVmax compared to SUVmean for the detection of high-risk patients. None of the investigated imaging parameters significantly outperformed SUVmax.

Conclusion: Our data confirm prior publications with lower number of patients that reported moderate correlations of PSMA PET parameters with clinical risk factors. With the important limitation that Gleason scores were only biopsy-derived in this study, there is no indication that the investigated additional parameters deliver superior information compared to SUVmax.

Keywords: PSMA; positron emission tomography; primary prostate cancer; prostate specific membrane antigen; quantitative PET parameters.

PubMed Disclaimer

Conflict of interest statement

HA declares research grants, travel grants, and lecture fees from Sirtex Medical Europe; HA confirms that none of the above funding sources were involved in the preparation of this paper. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Correlation between serum prostate-specific antigen (PSA) values and quantitative PSMA-PET parameters. (A) PSMA-derived tumor volume (PSMA-TV), (B) Maximum standardized uptake value (SUVmax), (C) Mean standardized uptake value (SUVmean) and (D) Tumor asphericity (ASP). PSA values are plotted on a logarithmic scale.
Figure 2
Figure 2
Correlation between Gleason scores obtained by biopsy before imaging and quantitative PSMA-PET parameters. (A) PSMA-derived tumor volume (PSMA-TV), (B) Maximum standardized uptake value (SUVmax), (C) Mean standardized uptake value (SUVmean) and (D) Tumor asphericity (ASP).
Figure 3
Figure 3
Boxplots showing the distribution of quantitative PET parameters for each Gleason score. (A) PSMA-derived tumor volume (PSMA-TV), (B) Maximum standardized uptake value (SUVmax), (C) Mean standardized uptake value (SUVmean) and (D) Tumor asphericity (ASP). Outliers are plotted as points (< 3 * interquartile range) or asterisks (> 3 * interquartile range).
Figure 4
Figure 4
Receiver operating characteristics (ROC) curves to detect high-risk prostate cancer using quantitative PSMA-PET parameters. (A) PSMA-derived tumor volume (PSMA-TV), (B) Maximum standardized uptake value (SUVmax), (C) Mean standardized uptake value (SUVmean) and (D) Tumor asphericity (ASP).
See this image and copyright information in PMC

References

    1. Petersen LJ, Zacho HD. PSMA PET for Primary Lymph Node Staging of Intermediate and High-Risk Prostate Cancer: An Expedited Systematic Review. Cancer Imaging (2020) 20:10. doi: 10.1186/s40644-020-0290-9 - DOI - PMC - PubMed
    1. Cytawa W, Seitz AK, Kircher S, Fukushima K, Tran-Gia J, Schirbel A, et al. . 68Ga-PSMA I&T PET/CT for Primary Staging of Prostate Cancer. Eur J Nucl Med Mol Imaging (2020) 47:168–77. doi: 10.1007/s00259-019-04524-z - DOI - PubMed
    1. Ambrosini V, Campana D, Polverari G, Peterle C, Diodato S, Ricci C, et al. . Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients With Neuroendocrine Tumors of the Pancreas. J Nucl Med (2015) 56:1843–8. doi: 10.2967/jnumed.115.162719 - DOI - PubMed
    1. Huang K, Schatka I, Rogasch JMM, Lindquist RL, De Santis M, Erber B, et al. . Explorative Analysis of a Score Predicting the Therapy Response of Patients With Metastatic, Castration Resistant Prostate Cancer Undergoing Radioligand Therapy With 177Lu-Labeled Prostate-Specific Membrane Antigen. Ann Nucl Med (2021) 35:314–20. doi: 10.1007/s12149-020-01567-3 - DOI - PMC - PubMed
    1. Komek H, Can C, Yilmaz U, Altindag S. Prognostic Value of 68 Ga PSMA I&T PET/CT SUV Parameters on Survival Outcome in Advanced Prostat Cancer. Ann Nucl Med (2018) 32:542–52. doi: 10.1007/s12149-018-1277-5 - DOI - PubMed